Skip to main content

Impact of cancer on the risk of unplanned 30-day readmissions.

Publication ,  Journal Article
Qian, A; Qiao, E; Nalawade, V; Kotha, NV; Voora, RS; Murphy, JD
Published in: Journal of Clinical Oncology
May 20, 2021

6581 Background: Hospital readmission are associated with unfavorable patient outcomes and increased costs to the healthcare system. Devising interventions to reduce risks of readmission requires understanding patients at highest risk. Cancer patients represent a unique population with distinct risk factors. The purpose of this study was to define the impact of a cancer diagnosis on the risks of unplanned 30-day readmissions. Methods: We identified non-procedural hospital admissions between January through November 2017 from the National Readmission Database (NRD). We included patients with and without a cancer diagnosis who were admitted for non-procedural causes. We evaluated the impact of cancer on the risk of 30-day unplanned readmissions using multivariable mixed-effects logistic regression models. Results: Out of 18,996,625 weighted admissions, 1,685,099 (8.9%) had record of a cancer diagnosis. A cancer diagnosis was associated with an increased risk of readmission compared to non-cancer patients (23.5% vs. 13.6%, p < 0.001). However, among readmissions, cancer patients were less likely to have a preventable readmission (6.5% vs. 12.1%, p < 0.001). When considering the 10 most common causes of initial hospitalization, cancer was associated with an increased risk of readmission for each of these 10 causes (OR range 1.1-2.7, all p < 0.05) compared to non-cancer patients admitted for the same causes. Compared to patients aged 45-64, a younger age was associated with increased risk for cancer patients (OR 1.29, 95%CI [1.24-1.34]) but decreased risk for non-cancer patients (OR 0.65, 95%CI [0.64-0.66]). Among cancer patients, cancer site was the most robust individual predictor for readmission with liver (OR 1.47, 95%CI [1.39-1.55]), pancreas (OR 1.36, 95%CI [1.29-1.44]), and non-Hodgkin’s lymphoma (OR 1.35, 95%CI [1.29-1.42]) having the highest risk compared to the reference group of prostate cancer patients. Conclusions: Cancer patients have a higher risk of 30-day readmission, with increased risks among younger cancer patients, and with individual risks varying by cancer type. Future risk stratification approaches should consider cancer patients as an independent group with unique risks of readmission.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2021

Volume

39

Issue

15_suppl

Start / End Page

6581 / 6581

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Qian, A., Qiao, E., Nalawade, V., Kotha, N. V., Voora, R. S., & Murphy, J. D. (2021). Impact of cancer on the risk of unplanned 30-day readmissions. Journal of Clinical Oncology, 39(15_suppl), 6581–6581. https://doi.org/10.1200/jco.2021.39.15_suppl.6581
Qian, Alexander, Edmund Qiao, Vinit Nalawade, Nikhil V. Kotha, Rohith S. Voora, and James Don Murphy. “Impact of cancer on the risk of unplanned 30-day readmissions.Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 6581–6581. https://doi.org/10.1200/jco.2021.39.15_suppl.6581.
Qian A, Qiao E, Nalawade V, Kotha NV, Voora RS, Murphy JD. Impact of cancer on the risk of unplanned 30-day readmissions. Journal of Clinical Oncology. 2021 May 20;39(15_suppl):6581–6581.
Qian, Alexander, et al. “Impact of cancer on the risk of unplanned 30-day readmissions.Journal of Clinical Oncology, vol. 39, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2021, pp. 6581–6581. Crossref, doi:10.1200/jco.2021.39.15_suppl.6581.
Qian A, Qiao E, Nalawade V, Kotha NV, Voora RS, Murphy JD. Impact of cancer on the risk of unplanned 30-day readmissions. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021 May 20;39(15_suppl):6581–6581.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2021

Volume

39

Issue

15_suppl

Start / End Page

6581 / 6581

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences